http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer
-
GBT Announces Participation at Upcoming Investor Conferences in March
-
GBT Announces New Employment Inducement Grants
-
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
-
GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
-
Pre-Open Movers 01/23: (RGSE) (CNET) (NFLX) Higher; (GPRO) (ADMS) (TWTR) Lower (more...)
-
Global Blood Therapeutics (GBT) Announces FDA Breakthrough Therapy Designation for Voxelotor for Treatment of SCD
-
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
-
GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
-
GBT Appoints Wendy L. Yarno to Board of Directors
-
Global Blood Therapeutics (GBT) Announces Presentation of Six Studies at ASH Supporting Voxelotor SCD Program
-
GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
-
Global Blood Therapeutics (GBT) Presents New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease
-
GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
-
Global Blood Therapeutics Announces New Employment Inducement Grants
-
Global Blood Therapeutics (GBT) Announces Completion of Safety Review by Independent DSMB for Phase 3 HOPE Study in SCD
-
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
-
Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference
-
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
-
Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting
-
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia
-
Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440
-
Global Blood Therapeutics (GBT) to Discontinue GBT440 Program for Treatment of IPF
-
Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program
-
Global Blood Therapeutics (GBT) Announces Presentation of New Data Showing Positive Effect of GBT440 on SCD Patient with Variant Genotype
-
Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
-
Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
-
Global Blood Therapeutics Announces New Employment Inducement Grants
-
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
-
Global Blood Therapeutics (GBT) Announces Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of SCD
-
Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
-
Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
-
Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
-
Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
-
Global Blood Therapeutics Announces New Employment Inducement Grants
-
Global Blood Therapeutics (GBT) Expands Phase 2a HOPE-KIDS 1 Study into Younger Pediatric
-
Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
-
Global Blood Therapeutics (GBT) Receives EMA PRIME Designation for GBT440 for Treatment of SCD
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
-
Global Blood Therapeutics (GBT) Reports New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease
-
Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease
-
Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference
-
Global Blood Therapeutics (GBT) Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at EHA
-
Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress
-
Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results
-
Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
-
Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results
-
Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March
-
Global Blood Therapeutics, Inc. (Nasdaq: GBT) to Ring The Nasdaq Stock Market Opening Bell
-
Global Blood Therapeutics, Inc. (Nasdaq: GBT) to Ring The Nasdaq Stock Market Opening Bell

